Rigel Pharmaceuticals

Rigel Launches VEPPANU for ESR1-Mutated Breast Cancer

South San Francisco, California, August 13, 2026 Rigel Pharmaceuticals, Inc. announced the U.S. commercial availability of VEPPANU™ (vepdegestrant) for...

By cGxPwire Editor
August 14, 2026

M&A

Rigel Expands Oncology Portfolio With VEPPANU Licensing Deal

SOUTH SAN FRANCISCO, Calif., May 12, 2026 Rigel Pharmaceuticals has entered into an exclusive global licensing agreement with Arvinas...

By cGxPwire Editor
May 13, 2026

Pharma

Rigel GAVRETO Shows Strong Survival in NSCLC Trial

SOUTH SAN FRANCISCO, Calif., USA, March 31, 2026 Rigel Pharmaceuticals has announced the publication of final Phase 1/2 ARROW...

By cGxPwire Editor
April 1, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

Rigel Pharmaceuticals

Rigel Launches VEPPANU for ESR1-Mutated Breast Cancer

Rigel Expands Oncology Portfolio With VEPPANU Licensing Deal

Rigel GAVRETO Shows Strong Survival in NSCLC Trial